Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

458 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Endpoint comparison for bone mineral density measurements in North Central Cancer Treatment Group cancer clinical trials N02C1 and N03CC (Alliance).
Dueck AC, Singh J, Atherton P, Liu H, Novotny P, Hines S, Loprinzi CL, Perez EA, Tan A, Burger K, Zhao X, Diekmann B, Sloan JA; Alliance for Clinical Trials in Oncology. Dueck AC, et al. Among authors: hines s. Osteoporos Int. 2015 Jul;26(7):1971-7. doi: 10.1007/s00198-015-3091-4. Epub 2015 Mar 7. Osteoporos Int. 2015. PMID: 25749740 Free PMC article. Clinical Trial.
Phase II Evaluation of Desipramine for the Treatment of Hot Flashes.
Barton DL, Loprinzi CL, Atherton P, Raymond J, Shanafelt T, Hines S, Palmieri F, Rummans T, Adjei AA, Sloan J. Barton DL, et al. Among authors: hines s. Support Cancer Ther. 2007 Sep 1;4(4):219-24. doi: 10.3816/SCT.2007.n.018. Support Cancer Ther. 2007. PMID: 18632520
Phase III randomized, placebo-controlled, double-blind trial of risedronate for the prevention of bone loss in premenopausal women undergoing chemotherapy for primary breast cancer.
Hines SL, Mincey BA, Sloan JA, Thomas SP, Chottiner E, Loprinzi CL, Carlson MD, Atherton PJ, Salim M, Perez EA. Hines SL, et al. J Clin Oncol. 2009 Mar 1;27(7):1047-53. doi: 10.1200/JCO.2008.19.1783. Epub 2008 Dec 15. J Clin Oncol. 2009. PMID: 19075260 Free PMC article. Clinical Trial.
Immediate versus delayed zoledronic acid for prevention of bone loss in postmenopausal women with breast cancer starting letrozole after tamoxifen-N03CC.
Hines SL, Mincey B, Dentchev T, Sloan JA, Perez EA, Johnson DB, Schaefer PL, Alberts S, Liu H, Kahanic S, Mazurczak MA, Nikcevich DA, Loprinzi CL. Hines SL, et al. Breast Cancer Res Treat. 2009 Oct;117(3):603-9. doi: 10.1007/s10549-009-0332-2. Epub 2009 Feb 12. Breast Cancer Res Treat. 2009. PMID: 19214743 Free PMC article. Clinical Trial.
5-year follow-up of a randomized controlled trial of immediate versus delayed zoledronic acid for the prevention of bone loss in postmenopausal women with breast cancer starting letrozole after tamoxifen: N03CC (Alliance) trial.
Wagner-Johnston ND, Sloan JA, Liu H, Kearns AE, Hines SL, Puttabasavaiah S, Dakhil SR, Lafky JM, Perez EA, Loprinzi CL. Wagner-Johnston ND, et al. Among authors: hines sl. Cancer. 2015 Aug 1;121(15):2537-43. doi: 10.1002/cncr.29327. Epub 2015 Apr 30. Cancer. 2015. PMID: 25930719 Free PMC article. Clinical Trial.
458 results